Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEACLIFF: AZD0516 Monotherapy and Combination with AZD9574 in Metastatic Castration-Resistant Prostate Cancer
jRCT2031250565Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of AZD0516 and palacaparib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability (AEs, SAEs, AESIs) - Modules 1 and 2, Parts A and B, Dose-limiting toxicities (DLTs) - Modules 1 and 2, Part A and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
AZD0516palacaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031250565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250565.